Zephyrnet Logo

Tag: Presentations

4 Ways to Develop Your Team’s Cyber Skills

Organizations need to invest in professional development — and then actually make time for it.

NASA foresees gap in lunar landings after Artemis 3

Starship

After landing astronauts on the moon in the mid-2020s for the first time in more than a half-century, NASA will wait at least two more years before making a second crewed lunar landing as part of the Artemis program.

SpaceNews

New RE/MAX ad campaign highlights importance of agents in tough times

The pandemic has been challenging for the industry, with agents and consumers navigating a wily housing market and the difficulties of pandemic life. To honor agents' tenacity, RE/MAX has a new ad campaign, "The Right Agent Can Lead the Way."

Greece Gambling Conference 2022

In a little over six weeks on the 1st March, Athens will host the Greece Gambling Conference 2022 dedicated to various aspects of the gambling business in Greece, the prospects for development of the gambling market in the country and the specifics of its legislative regulation. Situated in the Novotel Athens hotel with a fantastic […]

The post Greece Gambling Conference 2022 appeared first on Casinomeister.

ONE MONTH TO GO! Call for Sessions at SciDataCon, part of International Data Week 2022

Proposals are invited for sessions at International Data Week’s SciDataCon 2022: Data to Improve our World. The deadline for proposals is 23:59 UTC on 14 February 2022. Submit your session proposal at https://www.scidatacon.org/IDW-2022/submit/   About SciDataCon 2022 and International Data Week 2022 SciDataCon 2022 is part of International Data Week 2022, to be held virtually and in Seoul, […]

The post ONE MONTH TO GO! Call for Sessions at SciDataCon, part of International Data Week 2022 appeared first on CODATA, The Committee on Data for Science and Technology.

December 2021 saw a 23% drop in medical device clinical trials globally

The number of new clinical trials for medical devices in December 2021 saw a 23% decrease globally when compared with the last 12-month average, according to GlobalData’s medical devices clinical trials database. The global medical devices market was worth $479.97bn in 2020 and is expected to reach $532.37bn by 2023, according to GlobalData’s analysis. Medical …

The post December 2021 saw a 23% drop in medical device clinical trials globally appeared first on Medical Device Network.

Planned and ongoing medical device clinical trials drop 19% in December 2021 globally

The number of planned and ongoing clinical trials (new) for medical devices in December 2021 saw a decrease 19% globally when compared with the last 12-month average, according to GlobalData’s medical devices clinical trials database. The global medical devices market was worth $479.97bn in 2020 and is expected to reach $532.37bn by 2023, according to …

The post Planned and ongoing medical device clinical trials drop 19% in December 2021 globally appeared first on Medical Device Network.

Data Democratization: Think of It as Home Renovation

The focus of this article is on data democratization within the business enterprise, but the concepts and approaches involved in implementing this type of initiative are worth considering for any kind of major change within an organization.  When thinking about business environments – how they are established and how they evolve – it is often […]

The post Data Democratization: Think of It as Home Renovation appeared first on DATAVERSITY.

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

TOKYO, Jan 17, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

At this symposium, the results of a primary analysis of a prospective clinical study evaluating transcatheter arterial chemoembolization (TACE) therapy in combination strategy with lenvatinib (TACTICS-L) in patients with unresectable hepatocellular carcinoma (uHCC) in Japan (Abstract No: 417), as well as research updates on the Phase IV Study (STELLAR) to evaluate safety and tolerability of lenvatinib in patients with advanced/unresectable hepatocellular carcinoma (Abstract No: TPS485) and results from a clinical study to evaluate the efficacy of lenvatinib for conversion surgery in patients with uHCC (investigator-initiated study in Japan, Abstract No: 458), will be presented.

In addition, trial-in-progress (TiP) posters from the clinical program evaluating the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), include the Phase III LEAP-014 Study of the combination plus chemotherapy in patients with esophageal carcinoma squamous cell carcinoma (Abstract No: TPS367), Phase III LEAP-015 Study of the combination plus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma (Abstract No: TPS369), Phase III Study LEAP-012 of the combination plus TACE in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (Abstract No: TPS494), and Phase II Study of the combination plus belzutifan in patients with advanced solid tumors (Abstract No: TPS669).

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

About the Merck & Co., Inc., Kenilworth, N.J., U.S.A. and Eisai Strategic Collaboration

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A.

In addition to ongoing clinical studies evaluating the LENVIMA plus KEYTRUDA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.

Eisai's Focus on Cancer

Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

A Deep Look Into 13 Data Scientist Roles and Their Responsibilities

Any modern company of any significant size around the world has a data science department, and a data engineer at one company might have the same responsibilities as a marketing scientist at another company. Data science jobs are not well-labeled, so make sure to cast a wide net.

Intel and Nvidia just dunked on Apple’s M1 Max. Should you believe the hype?

Let’s Play! Raising the Stakes for Threat Modeling With Card Games

On a recent Friday night, three security experts got together to play custom games that explore attack risks in an engaging way.

Latest Intelligence

spot_img
spot_img

Chat with us

Hi there! How can I help you?